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Recently, inflammatory mediators such as TNFa were identified as triggering active human cytomegalovirus (HCMV)
infection. Here, we demonstrate that a highly stressful event in the absence of systemic inflammation, as observed in patients
with acute myocardial infarction, leads to the development of an active HCMV infection in latently infected patients.
Elucidating the molecular mechanism of virus activation, we could show that catecholamines directly stimulate the HCMV
immediate-early (IE) enhancer/promoter in monocytic cells via b-2 adrenergic receptors. Subsequent activation of the
cAMP/PK-A-signaling pathway results in enhanced synthesis and binding of the transcription factor CREB-1/ATF-1 to the
cAMP-responsive elements within the IE enhancer. Epinephrine also enhanced HCMV gene expression in infected THP-1
cells by about 50% in three of four experiments. These data suggest that HCMV, like HSV-1 and VZV, can be (re)activated
under stress conditions. © 2000 Academic Press
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oINTRODUCTION
Active infections with the human cytomegalovirus
(HCMV) play an important role in the morbidity and case
fatality of organ and bone marrow transplant recipients
and AIDS patients. In addition to the risk of those pa-
tients developing classical signs of acute and chronic
HCMV disease (e.g., fever, leukopenia, pneumonitis,
hepatitis, retinitis), active HCMV infections may be asso-
ciated with acute and chronic graft failure (Grattan et al.,
1989; Reinke et al., 1994) and secondary immune defi-
ciency (Fishman and Rubin, 1989). However, their patho-
logical significance seems not to be restricted to immu-
nocompromised patients.
Active HCMV infections result mostly from reactivation
of latent virus harbored by more than 60% of adults.
Granulocyte/monocyte progenitors in the bone marrow
were identified as at least one site of HCMV latency
(Taylor-Wiedeman et al., 1991; Mendelson et al., 1996;
Kondo et al., 1996). Very recently reactivation of latent
HCMV from blood monocytes and latently infected gran-
ulocyte/monocyte progenitors has been described
(So¨derberg-Naucler et al., 1997; Hahn et al., 1998). Ex-
pression of the major immediate-early (IE) proteins IE-1
and IE-2 was shown to be critical for transition from
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357latency to productive infection (Iskenderian et al., 1996;
Greaves and Mocarski, 1998). Expression of these pro-
teins is controlled by the major IE enhancer/promoter
whose activity depends on both viral and cellular factors/
proteins (for review see Meier and Stinski, 1996).
Recently, by clinical studies and in vitro experiments
we have demonstrated that systemic inflammation, in
particular TNFa release, may be an important cofactor
or HCMV (re)activation in transplant patients as well as
onimmunosuppressed patients with septicemia or
ther inflammatory diseases through up-regulation of the
E enhancer/promoter activity by NF-kB (Stein et al.,
993; Do¨cke et al., 1994; Fietze et al., 1994; Pro¨sch et al.,
995, 1998b). These observations were confirmed by
thers demonstrating TNFa-mediated HCMV reactiva-
tion in latently infected monocyte/granulocyte progenitor
cells (Hahn et al., 1998) as well as ex vivo reactivation of
MCMV from bone marrow myelomonocytes that were
isolated from latently infected animals (Henry, 1999).
However, in humans, active HCMV infection has been
also observed in patients without any signs of a systemic
inflammation. HCMV-associated encephalitis and colitis
have been reported in nonimmunosuppressed patients
(Studahl et al., 1992; Blair et al., 1992; Maignan et al.,
1992; Pro¨sch et al., 1998a). Furthermore, increased prev-
alence of HCMV seropositivity and higher serum anti-
HCMV IgG levels were reported in nonimmunosup-
pressed, nonmalignant patients with peptic ulcer and
nonulcer dyspepsia as well as in healthy people under
physical stress (Glaser et al., 1985; Archimandritis et al.,
1992). An association was found between stress-produc-
0042-6822/00 $35.00
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358 PRO¨SCH ET AL.ing events and the number of HCMV DNA-positive urine
and leukocyte samples (Toro and Ossa, 1996). These
data suggest that stressful conditions may induce mo-
lecular events that promote (re)activation of HCMV ex-
pression and replication, but the mechanism(s) is still
unknown.
A relationship between physical or psychic stress and
reactivation of other members of the herpesvirus family,
e.g., herpes simplex virus (HSV), is well established (for
reviews see Steiner, 1996; Turner and Jenkins, 1997).
Stress induces the release of several mediators such as
catecholamines, glucocorticoids, and thyroid hormones
from the synaptic nervous system and endocrine glands.
In animal models and clinical studies it has been shown
that stressors such as epinephrine, cyclophosphamide,
transient hyperthermia, UV light, and glucocorticoids in-
duce (re)activation of HSV (Perna et al., 1987; Steiner,
1996; Turner and Jenkins, 1997). However, the molecular
mechanism(s) underlying these processes is poorly un-
derstood.
The aim of the present study was to investigate the
relation between stress and (re)activation of HCMV in-
fection in humans. In a prospective clinical study we
investigated the incidence of active HCMV infection in
patients with acute myocardial infarction—a highly
stressful event that was shown to be associated with
strongly elevated catecholamine but normal TNFa
plasma levels. By in vitro experiments a direct stimula-
tory effect of catecholamines on the activity of the HCMV
IE enhancer/promoter and on viral gene expression
could be identified.
RESULTS
Catecholamine release in myocardial infarction is
associated with HCMV activation
In a prospective clinical study, 10 patients with acute
myocardial infarction were monitored for plasma epi-
nephrine and norepinephrine levels as well as for pa-
rameters of HCMV infection from intensive care unit
admission up to 14 days after the acute event. Catechol-
amine plasma concentrations were enhanced at admis-
sion and normalized on day 4 after myocardial infarction
(Fig. 1). There was a positive correlation between epi-
nephrine and norepinephrine plasma levels, which was
strongest on day 1 (r 5 0.81, P 5 0.005; Pearson
coefficient with two-tailed significance levels).
Nine of the 10 patients (90%) had IgG anti-HCMV
antibodies in serum. The levels increased in 5 of 9
patients during the 2-week follow-up. Specific IgM was
never detectable. None of the patients with myocardial
infarction established HCMV disease-related symptoms
within the observation period of 14 days. However, all
patients developed positive HCMV DNA PCR from pe-
ripheral blood mononuclear cells (PBMC) during the first
week. One day after admission, HCMV DNA was alreadydetectable in 5 of 8 patients tested, and within the first 4
days all 10 patients were PCR-positive including the one
patient who was (and remained) seronegative. Thereaf-
ter, the prevalence of positive HCMV DNA PCR dropped
again; on day 14 only 2 of 7 patients (3 patients had been
discharged from the hospital before) were still positive.
Moreover, using immunocytology, on day 1, in 3 of the
10 patients at least one cell per 10,000 PBMC was found
to be positive for HCMV IE or early antigens (Fig. 2). The
mean frequency of HCMV antigen-positive cells, as as-
sessed by summation of the counts for three different
antibodies, was as low as 1.62 6 0.92 HCMV antigen-
positive cells per 10,000 PBMC (mean 6 SEM), which
was comparable to this level in healthy probands (0.64 6
0.21 per 10,000 PBMC, P . 0.05 in a Mann–Whitney U
test). On day 4, 8 patients already had HCMV antigen-
positive PBMC with a slightly increased frequency of
5.66 6 2.04 per 10,000 cells (P , 0.05 vs day 1; P ,
0.001 vs controls). Seven days after the acute myocardial
infarction all 10 patients had developed a strong HCMV
antigenemia with a mean frequency of 91.47 6 25.61
HCMV antigen-positive cells per 10,000 PBMC (P , 0.01
vs day 1 and vs day 4). Interestingly, this peak frequency
of HCMV antigen-positive cells was significantly corre-
lated to postinfarction peak plasma levels of both nor-
epinephrine (r 5 0.78, P 5 0.005) and epinephrine (r 5
0.63; P 5 0.039). Moreover, the highest frequencies of
HCMV antigen-positive cells (189 and 275 per 10,000
PBMC, respectively) were found in 2 patients who pre-
sented with cardiogenic shock at admission and needed
catecholamine infusions.
Two weeks after the acute event, HCMV antigenemia
markedly declined in the remaining seven patients in-
vestigated although the number of positive cells was still
significantly elevated (4.51 6 1.63 per 10,000 PBMC) in
FIG. 1. Myocardial infarction is associated with sympathetic hyper-
activity. Norepinephrine and epinephrine serum levels were deter-
mined by HPLC in patients with acute myocardial infarction (normal
ranges 165–460 and 30–90 pg/ml, respectively). Data are given as
means 6 SEM. *P , 0.05, **P , 0.01 vs admission, Wilcoxon test.comparison to day 1 (P , 0.05) and healthy probands
(P , 0.001).
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359CATECHOLAMINE-TRIGGERED HCMV (RE)ACTIVATIONWhen looking at the different HCMV antigens, at all
time points the highest frequency of positive cells was
found for the IE-1 antigen. On day 7 after myocardial
infarction, however, the frequencies for all HCMV anti-
gens investigated were significantly enhanced in com-
parison to day 1 (for IE-1 antigen, 56.5 6 12.9 vs 1.7 6 0.5
antigen-positive cells per 10,000 PBMC; for pp65 antigen,
20.5 6 4.7 vs 0.6 6 0.4 antigen-positive cells per 10,000
PBMC; for p52 antigen, 15.3 6 4.1 vs 0.6 6 0.4 antigen-
positive cells per 10,000 PBMC). The majority of infected
cells were monocytes; however, positive lymphocytes
were detected too (not shown).
Catecholamines stimulate the HCMV IE enhancer/
promoter in monocytic cells
To verify a direct role of catecholamines in stimulation
of active HCMV infection, we studied their influence on
HCMV IE enhancer/promoter activity in the monocytic
cell line THP-1, which is semipermissive for HCMV
(Weinshenker et al., 1988) and may serve as a model of
actively infected monocyte/macrophages in vivo.
As demonstrated in Fig. 3A, the catecholamines epi-
nephrine and norepinephrine, but not the stress hor-
FIG. 2. Myocardial infarction triggers HCMV antigenemia. HCMV
antigen-positive cells were determined for 10 patients with acute myo-
cardial infarction. The overall frequency of HCMV antigen-positive
PBMC as determined by the APAAP technique using mAb recognizing
HCMV IE-1 antigen, pp65 early matrix protein, and p52 early DNA
binding protein was calculated by summarizing those positive for the
different antigens. Individual values are shown. The mean frequency
(6SEM) of antigen-positive cells per 10,000 PBMC for all patients was
1.62 6 0.92 on day 1; 5.66 6 2.04 on day 4 (P , 0.05); 91.47 6 25.61
on day 7 (P , 0.01); and 4.51 6 1.63 on day 14 (P , 0.05 vs day 1;
Wilcoxon test). For comparison, the results from 32 seropositive blood
donors are given (mean frequency of HCMV antigen-positive cells:
0.64 6 0.21 per 10,000 PBMC). The frequencies of HCMV antigen-
positive cells in our patient group were comparable to those in healthy
controls on day 1 (P . 0.05) but significantly enhanced on days 4, 7,
and 14 after myocardial infarction (P , 0.001, P , 0.0001, and P ,
0.001 in a Mann–Whitney U test).mones thyroxine and ACTH, caused a strong stimulation
of the IE enhancer/promoter-controlled CAT expression
e
ein pRR55-transfected THP-1 cells. Marginal stimulation
was also observed in corticosteroid-treated cells. The
stimulatory effect of epinephrine and norepinephrine
was concentration-dependent (Fig. 3B). Catecholamines
also significantly stimulated the IE enhancer/promoter
activity in transfected freshly isolated monocytes from
buffy coat of healthy blood donors by factor of 2.5 to 3
(data not shown).
Catecholamine stimulation is mediated via the b-2-
drenoreceptors and involves protein kinase A
To learn more about the mechanisms of catechol-
mine-dependent stimulation of the IE enhancer/pro-
oter, pRR55-transfected THP-1 cells were preincubated
ith increasing concentrations of the b-adrenergic re-
FIG. 3. Influence of stress hormones on the HCMV IE enhancer/
romoter activity in pRR55-transfected THP-1 cells. (A) Selective stim-
lation by catecholamines. After transfection with plasmid pRR55,
HP-1 cells were incubated in the absence (control) or in the presence
f 500 ng/ml epinephrine (E), norepinephrine (NE), thyroxine (Thyr.),
CTH, or dexamethasone (Dexa.). Cells were harvested after 40 h for
AT assay. The graph represents the relative CAT expression rate of
our independent experiments (means 6 SEM); significance was dem-
nstrated in Friedman test (P , 0.05). (B) Dose-dependent effects of
pinephrine and norepinephrine. pRR55-transfected THP-1 cells were
ncubated with different concentrations of epinephrine or norepineph-
ine. The graph represents mean (6SEM) values of relative CAT ex-
ression rates obtained in four independent experiments. For bothp
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ppinephrine and norepinephrine, significant dose-dependent differ-
nces were demonstrated by the Friedman test (P , 0.01).
e360 PRO¨SCH ET AL.ceptor blockers propranolol and metoprolol. Whereas
the selective b-1-receptor antagonist metoprolol had no
ffect, propranolol, which blocks both b-1- and b-2-ad-
renergic receptors, completely abrogated the stimulatory
effect of epinephrine (Fig. 4A) and norepinephrine (data
not shown).
The majority of effects downstream from the b-2-ad-
renergic receptor are known to be mediated by the
cAMP/protein kinase (PK)-A-dependent signaling path-
way. Therefore, we tested the effect of the PK-A inhibitor
H89 on epinephrine/norepinephrine-dependent stimula-
tion. Preincubation of pRR55 transfected THP-1 cells with
H89 (Fig. 4B) but not with the PK-C inhibitor H7 (data not
shown) reduced the stimulatory effect of epinephrine on
IE promoter activity in a dose-dependent manner. High
FIG. 4. The catecholamine effect is mediated through b-2-adrenore-
ceptors and protein kinase A activation. THP-1 cells transfected with
the plasmid pRR55 were incubated in the absence (control) or in the
presence of epinephrine (500 ng/ml) and different concentrations of the
b-1/b-2-adrenoreceptor blocker propranolol (A) or the protein kinase A
inhibitor H89 (B). Propranolol or H89 was added at time zero after
transfection and 60 min before addition of epinephrine. The mean
values (6SEM) of relative CAT expression determined in four indepen-
dent experiments (propranolol) and three independent experiments
(H89) are presented. For both agents, significant dose-dependent dif-
ferences in CAT expression were demonstrated in the epinephrine
group (P , 0.05, Friedman test).but nontoxic concentrations of H89 (but not of H7) also
down-regulated the basal activity of the HCMV IE en-hancer/promoter, which had been shown to depend
mainly on the activity of the CREB-1/ATF-1 transcription
factor (Stamminger et al., 1990).
Catecholamines target a CRE-containing 19-bp
sequence motif of the HCMV IE enhancer
The enhancer of the HCMV IE promoter contains five
19-bp repetitive sequence motifs each containing a
cAMP-responsive element (CRE), which binds the tran-
scription factor CREB-1/ATF-1 (Hunnighake et al., 1989;
Meier and Stinski, 1996). To prove whether the stimula-
tory effect of catecholamines is mediated via the known
CRE in the 19-bp sequence motifs of the IE enhancer,
THP-1 cells were transfected with plasmid constructs
containing the minimal IE promoter alone (pUPCAT) or in
combination with four in-tandem copies of the 19-bp
sequence motif with the CRE (p4-19PCAT). Control trans-
fections were performed with plasmid constructs con-
taining the minimal IE promoter and four in-tandem
copies of the 18-bp sequence motif including a NF-kB-
binding site (p4-18PCAT), the 17-bp sequence motif (p4-
17PCAT), or the 21-bp sequence motif (p4-21PCAT).
Epinephrine had no effect on CAT expression in cells
transfected with plasmids containing the minimal pro-
moter alone or in combination with either the 17- or the
21-bp sequence motifs (data not shown). Only marginal
stimulation was observed in p4-18PCAT transfected cells
(Fig. 5). In contrast, a very strong stimulation of CAT
expression occurred in those cells transfected with the
plasmid p4-19PCAT as well as in cells transfected with
the plasmid p4-18/4-19PCAT (Fig. 5). As for the complete
IE enhancer/promoter, stimulation via the CRE-contain-
ing 19-bp sequence motifs was decreased by H89 (70%
inhibition of the epinephrine-dependent stimulation) but
not by H7 (0% inhibition) and could be antagonized by
FIG. 5. Catecholamines target the 19-bp sequence motif of the
HCMV IE enhancer. THP-1 cells were transfected with the plasmid
constructs p4-18PCAT, p4-19PCAT, or p4-18/4-19PCAT and incubated in
the absence (control) or in the presence of 500 ng/ml epinephrine or
norepinephrine. Mean (6 SEM) values of relative CAT conversion rates
o
tf five independent experiments are presented. *P , 0.05 vs respec-
ive control, Wilcoxon test; °P , 0.05 vs p4-18CAT, Wilcoxon test.
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361CATECHOLAMINE-TRIGGERED HCMV (RE)ACTIVATIONpropranolol (90% inhibition), indicating that the CREs
indeed mediate the catecholamine-induced stimulation
of the IE enhancer/promoter and this occurs via the
b-2-adrenergic receptor.
Catecholamines increase synthesis of CREB-1 and
the binding activity of CREB-1/ATF-1 to the CREs
In an electrophoretic mobility shift assay (EMSA), a
significantly increased protein-binding activity of the
19-bp sequence motif was evident in nuclear extracts
from epinephrine- or norepinephrine-treated THP-1 cells
(Fig. 6A, lanes 3 and 1, respectively) compared to the
nuclear extract from untreated THP-1 cells (lane 2). Bind-
ing of the protein(s) was highly specific and could be
completely competed by preincubation of the nuclear
extract with unlabeled 19-bp oligonucleotide (data not
shown) and an oligonucleotide concerning the CRE con-
sensus sequence (Fig. 6A, lanes 4, 5, and 10). Moreover,
the bound protein complex reacted in supershifts with
antibodies specific for the transcription factors ATF-1 and
CREB-1 (Fig. 6A, lanes 6–9, 11, and 12) but not with
antibodies against NF-kB p65 and AP-1/c-jun (data not
shown).
In Western blot analysis using nuclear extracts from
untreated and catecholamine-treated THP-1 cells and a
polyclonal antiserum specific for CREB-1 we observed
an increased amount of CREB-1 protein (p43) in cate-
cholamine-treated cells (Fig. 6B, lanes 7 and 8) com-
pared to untreated cells (Fig. 6B, lanes 5 and 6). To
demonstrate equivalent loading of nuclear proteins a
Coomassie blue-stained gel is shown in Fig. 6B, lanes
2–4.
Epinephrine enhances HCMV gene expression in
infected THP-1 cells
Next we wondered whether epinephrine stimulates
HCMV gene expression in virus-infected monocytic cells.
THP-1 cells were infected with the recombinant HCMV
RC256 expressing b-galactosidase and proven to have
b-galactosidase activity 72 h postinfection using the
O-nitrophenyl-b-D-galactopyranoside method (MacGre-
or et al., 1991). In three of four independent experiments
00 ng/ml epinephrine enhanced b-galactosidase ex-
pression by about 50% as shown in Table 1.
DISCUSSION
Recently, TNFa was identified as an important risk
actor for (re)activation of HCMV infection in several
atient groups (Do¨cke et al., 1994; Fietze et al., 1994). By
in vitro experiments we could show that TNFa up-regu-
ates the activity of the major HCMV IE enhancer/pro-
oter in premonocytic cells (Stein et al., 1993; Pro¨sch et
al., 1995, 1998b). Accordingly, TNFa was shown to me-
diate reactivation of HCMV in latently infected progenitor
cells (Hahn et al., 1998).The present study defines an additional novel risk
FIG. 6. (A) Catecholamines increase the binding activity of CREB-1/
ATF-1 to the CREs of the 19-bp sequence motif of the HCMV IE
enhancer. Radiolabeled oligonucleotides with the 19-bp sequence mo-
tif of the IE enhancer were incubated with nuclear extracts of THP-1
cells incubated for 12 h in the absence (co) or in the presence of 500
ng/ml epinephrine (E) or norepinephrine (NE). Specificity of the binding
was verified by preincubation (5 min) of the nuclear extract with a 50
molar excess of an oligonucleotide containing the CRE consensus
sequence (CREc) (Santa Cruz Biotechnology, Santa Cruz, CA). For
identification of the bound protein complex, 1.5 ml of the antibodies
specific for CREB-1 (CREB) and ATF-1 (ATF) (Santa Cruz Biotechnology)
was added to the reaction mix. The autoradiograph shows one repre-
sentative experiment that was repeated four times. *Slower migrating
protein complex after incubation with the appropriate antibody. (B)
Epinephrine and norepinephrine enhance CREB-1 synthesis in THP-1
cells. Nuclear protein extracts from untreated (co), epinephrine-treated
(500 ng/ml; E), or norepinephrine-treated (500 ng/ml; NE) THP-1 cells
were analyzed for CREB-1 (p43) protein amounts by Western blot (lanes
5–8). For loading control a gel with identical probes was stained with
Coomassie blue (lanes 2–4). In lane 1, a protein molecular weight
standard is shown. The figure demonstrates one representative blot
that was repeated three times.factor of HCMV (re)activation and demonstrates a close
link between stress-related catecholamine response and
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362 PRO¨SCH ET AL.HCMV infection. Within a few days following the highly
stressful event of acute myocardial infarction, all 10 pa-
tients developed HCMV antigenemia, particularly in
monocytes, which are a site of viral reactivation from
latency (So¨derberg-Naucler et al., 1997). Although myo-
cardial infarction induces a local inflammation in the
ischemic tissue, we could not find a significant increase
of TNFa plasma levels in these patients (data not
hown). Therefore, it is unlikely that the active HCMV
nfection was due to systemic inflammation.
There was a strong correlation, however, between
atecholamine plasma peak levels in the early postin-
arction period and the frequency of HCMV antigen-
ositive cells on day 7. As the half-life of monocytes in
he peripheral blood is less than 24 h, we can presume
hat catecholamines triggered HCMV protein synthesis
n the monocytic bone marrow progenitor cells. A similar
elay between the triggering event and appearance of
CMV antigenemia was observed following OKT3-in-
uced TNFa release in transplant patients (Fietze et al.,
994), suggesting that bone marrow progenitor cells are
n important pool of HCMV at latency/persistence (Tay-
or-Wiedeman et al., 1991; Mendelson et al., 1996; Kondo
t al., 1996).
Our in vitro studies support for the first time a strong
elation between catecholamines and HCMV activity in
onocytic cells. In the presence of epinephrine, viral
ene expression (as measured by b-galactosidase ex-
pression) in RC256-infected THP-1 cells representing
mature monocytes was increased by about 50% in three
of four experiments. In transient transfection experi-
ments using the same cell line, catecholamines directly
stimulated the HCMV IE promoter via the b-2-adrenergic
receptor.
Similarly, HSV-1 reactivation by hyperthermia involves
this receptor also (Gebhardt and Kaufman, 1995). Follow-
ing binding of the hormone, a signal cascade is triggered
involving stimulation of PK-A and enhanced synthesis of
TABLE 1
Influence of Epinephrine on HCMV Gene Expression
in RC256-Infected THP-1 Cells
Experiment
No.
Control b-gal-
activity (Units)
Epinephrine (500 ng/ml)
b-gal-activity (Units)
Stimulation
factor
I 0.52 0.78 1.5
II 0.48 0.32 0.7
III 2.40 3.90 1.63
IV 1.48 2.18 1.5
Note. THP-1 cells (106) were infected with HCMV strain RC256 (m.o.i.
5 1) and cultivated in the absence or in the presence of 500 ng/ml
epinephrine. After 72 h, cell extracts were prepared and measured for
b-galactosidase activity by the ONPG method. Data from four indepen-
dent experiments are shown.the transcription factor complex CREB-1/ATF-1, which
specifically binds to the CRE-containing 19-bp repetitive
r
isequence motifs of the IE enhancer/promoter (Hun-
nighake et al., 1989). The transcriptional activity of CREB-
1/ATF-1 requires phosphorylation at serine 133, which is
known to be also regulated by the cAMP-dependent
PK-A (Gonzalez et al., 1989). Thus, in addition to the
demonstrated increased synthesis, enhanced phosphor-
ylation of the constitutively expressed transcription factor
complex CREB-1/ATF-1 might be responsible for the
stimulation of HCMV IE promoter-controlled transcription
by epinephrine and norepinephrine. As a consequence,
the key proteins of HCMV activation—the viral IE pro-
teins—are synthesized. Interestingly, stimulation of
HCMV activation and replication via the same cAMP-
dependent intracellular signaling pathway has been
demonstrated very recently for the drug pentoxifylline
both in vitro and in vivo (Staak et al., 1997). In contrast to
TNFa-mediated stimulation of the IE enhancer/promoter,
F-kB, which acts via the 18-bp repetitive sequence
motifs (Sambucetti et al., 1989; Pro¨sch et al., 1995), is not
or is only marginally involved in the catecholamine-in-
duced HCMV activation.
It has been described that stress mediators may
down-regulate the immune system, particularly the cell-
mediated immune response, which plays a key role in
the control of HCMV infection. Thus, an increase of
HCMV antigenemia could simply occur due to reduced
immune responsiveness. We monitored the monocytic
HLA-DR and CD86 expression as well as the plasma
IL-10 levels in the present study because these param-
eters are very sensitive indicators of stress-mediated
immune depression (Woiciechowski et al., 1998). In fact,
the patients showed slightly increased IL-10 plasma lev-
els (mean 7.4 pg/ml) at the time of admission but not later
(,5 pg/ml). The percentage of HLA-DR and CD86 anti-
gen-expressing CD141 monocytes did not significantly
hange during the follow-up period, whereas the mean
luorescence intensity was significantly decreased at
ays 1 and 2 by about 40–50%. Thereafter both param-
ters completely recovered, suggesting a moderate im-
unodepression, which was short-lasting and cannot
xplain the HCMV antigenemia peak level at day 7.
As stress is a common event, HCMV (re)activation may
ccur more frequently than previously thought and not
nly in immunosuppressed patients. Why is HCMV dis-
ase then a rare event, which is mostly restricted to
mmunocompromised patients? HCMV infection is con-
rolled in particular by T-cell-mediated immunity. In fact,
-cell immunodeficiency is associated with an increased
isk of developing HCMV-related disease. Using a novel
low cytometric technique we could demonstrate a very
igh frequency of HCMV antigen-reactive effector T-cells
n the peripheral blood of healthy seropositive donors
ithout any previous history of HCMV-related disease;
p to 2% of T-cells produced IFN-g, TNFa, or IL-2 inesponse to one HCMV-derived epitope within ,6 h of
ncubation (Kern et al., 1998)! The reactive T-cells ex-
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363CATECHOLAMINE-TRIGGERED HCMV (RE)ACTIVATIONpress a typical effector/memory phenotype (CD11a-high,
CD282). This observation gives strong evidence for a
epeated contact of the immune system with HCMV
ntigen even in healthy persons and supports our view
hat HCMV activation is a common event, e.g., under
tressful conditions. In nonimmunosuppressed individu-
ls, however, HCMV antigen-expressing cells are rapidly
liminated by the specific effector T-cells. Therefore,
etection of HCMV antigenemia should be a rare and
ery temporary event in immunocompetent humans.
It is difficult to speculate on what might be the clinical
onsequences of HCMV (re)activation in myocardial in-
arction. The fast elimination of HCMV-expressing cells
ithin 2 weeks suggests that the T-cell immunity is not or
s only temporarily diminished in these patients. This
ay also explain the absence of any typical HCMV dis-
ase-related symptoms. However, even if the active virus
nfection is rapidly controlled by T-cells, an inflammatory
rocess may be triggered. Further studies in this direc-
ion would be interesting, particularly with respect to the
iscussed association between HCMV infection and the
isk of restenosis after coronary atherectomy (Zhou et al.,
996). Such studies may be also of interest for the un-
erstanding of the pathophysiology of several diseases
or which a relation to HCMV infection is under discus-
ion, such as cardiac allograft vasculopathy (Grattan et
l., 1989), atherosclerosis (Danesh et al., 1997; Chiu et
l., 1997), and kidney transplant injury (Fishman and
ubin, 1989; Reinke et al., 1994).
In summary, our data suggest that in addition to in-
lammatory mediators (TNFa) and some cAMP-elevating
drugs (e.g., pentoxifylline) stress-induced and even ther-
apeutically applicated catecholamines may contribute to
(re)activation of HCMV infection in both immunocompro-
mised and nonimmunocompromised patients by a direct
stimulatory effect on HCMV gene expression. It further
illustrates that HCMV is using very different cellular fac-
tors for its activation and replication, underscoring the
excellent adaptation of the virus to its host. Commonly, a
sufficient T-cell immunity controls the HCMV antigen-
expressing cells in nonimmunocompromised patients
but a temporary HCMV-specific T-cell-triggered inflam-
matory response may contribute to HCMV-associated
pathophysiology.
MATERIALS AND METHODS
Patients
Ten patients (7 males, 3 females; mean age 60 years,
range 46–75 years) without known infectious or inflam-
matory disorders and with the clinical diagnosis of acute
myocardial infarction and typical ECG changes for an
anterior (n 5 3) or a posterior (n 5 7) infarct were
included in the study. The diagnosis was confirmed with
serum analysis of cardiac enzymes and coronary angio-
grams. Four of 10 patients underwent systemic throm-
c
3bolysis, 3 patients received a coronary angioplasty, and
one patient needed a percutaneous transluminal coro-
nary angioplasty after nonsuccessful thrombolysis.
Three patients received catecholamine infusions be-
cause of cardiogenic shock. All but 2 patients were
discharged.
The study was approved by the Institutional Review
Board and informed consent was obtained from all pa-
tients.
Catecholamine determination
Catecholamine concentrations in plasma were deter-
mined using high-performance liquid chromatography as
described by Ganhao et al. (1991).
HCMV serology
Serum IgM and IgG anti-HCMV antibodies were de-
termined by the ELISA technique using the ETI-cytok G
(Sorin Biomedica, Sallugia, Italy) and HCMV IgM-ELA
test (Medac GmbH, Hamburg, Germany), respectively.
Positivity was defined according to the manufacturers’
criteria.
HCMV antigen test in PBMC
HCMV antigenemia was tested by immunocytology
(APAAP technique) on PBMC as described previously
(Fietze et al., 1994) using monoclonal antibodies (mAb)
recognizing HCMV immediate-early antigen-1 (Clonab
CMV IE1, Clone BS 500; Biotest, Frankfurt, Germany),
pp65 early matrix protein (Clonab CMV, Clone C10/C11;
Biotest), or p52 early DNA binding protein (Clone CCH2;
Dako, Hamburg, Germany). Isotype-matched irrelevant
and anti-leucocyte common antigen mAbs (Clone: DAKO-
LCA; Dako) were used as negative and positive controls,
respectively. For each mAb 10,000–15,000 PBMC were
studied by microscopy.
HCMV DNA PCR
For PCR, DNA was isolated from PBMC by proteinase
K digestion (100 mg/ml; 1 h, 65°C) followed by phenol/
hloroform extraction and ethanol precipitation as de-
cribed elsewhere (Pro¨sch et al., 1992). The primers
ere complementary to the IE region generating a
23-bp fragment; the identity of PCR products was veri-
ied by Southern hybridization with a radiolabeled inter-
al oligonucleotide (Olive et al., 1989). Routinely 40 cy-
les of amplification were carried out. The lower detec-
ion threshold was at least 50 HCMV DNA copies.
ells and virus
THP-1 cells (TIB 202) were cultured in RPMI 1640
edium supplemented with 10% fetal calf serum (bothertified endotoxin-free; Biochrome, Berlin, Germany) at
7°C in a 5% humidified atmosphere. The cells were
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tection Kit (Boehringer Mannheim, Mannheim, Germany).
The b-galactosidase-expressing recombinant HCMV
C256 (constructed in the laboratory of Edward Mocar-
ki, Stanford University) was kindly provided by J. Mac-
iewski (NIH, Bethesda, MD). THP-1 cells were infected
ith an m.o.i. 5 1. After adsorption was allowed to
roceed for 1 h at 37°C the infected cells were cultivated
s described above.
lasmids, transfection, and CAT assay
The plasmid pRR55 contains the whole native imme-
iate-early enhancer/promoter region of AD169 virus
train between nucleotides 2671 and 152 relative to the
IE-1/IE-2 transcription start site upstream of the CAT
reporter gene. The plasmids p4-19PCAT, p4-18PCAT, p4-
17PCAT, and p4-21PCAT carry the minimal promoter be-
tween 256 and 152 relative to the IE-1/IE-2 transcription
start site and four in-tandem copies of the 19-, 18-, 17-, or
21-bp repetitive sequence motifs of the enhancer (Stam-
minger et al., 1990). The plasmids were kindly provided
by T. Stamminger (Erlangen, Germany). Plasmid p4-19/4-
18PCAT, constructed in our laboratory, contains four cop-
ies of each the 19- and the 18-bp sequence motifs up-
stream of the minimal IE promoter and the CAT gene.
Plasmid transfection of THP-1 cells by the DEAE-dex-
tran method and CAT assay were performed as de-
scribed in detail elsewhere (Stein et al., 1993).
Electrophoretic mobility shift assay
Preparation of nuclear extracts was carried out as
described (Pro¨sch et al., 1995). As target DNA for EMSA
we used an oligonucleotide containing the 19-bp se-
quence motif of the IE enhancer. Oligonucleotides were
radiolabeled by filling in recessed ends with Klenow
enzyme (Boehringer Mannheim) and [a-32P]dCTP (Hart-
mann, Braunschweig, Germany). For EMSA, 9 mg of nu-
lear extract was incubated with 0.5 to 1.0 ng radiola-
eled oligonucleotide in a 20-ml reaction volume contain-
ing the appropriate binding buffer (Pro¨sch et al., 1995;
Staak et al., 1997). After binding at room temperature for
20 min, the DNA–protein complexes were separated on
a 5% nondenatured polyacrylamide gel.
Western blot analysis
Nuclear protein extracts (50 mg) from untreated or
pinephrine/norepinephrine-treated THP-1 cells were
enatured for 3 min at 100°C in Laemmli buffer, sepa-
ated on a 12% SDS–polyacrylamide gel, and transferred
o nitrocellulose membrane (Schleicher & Schu¨ll, Dassel,
ermany). To avoid nonspecific binding, membranes
ere blocked for 12 h in TBS containing 10% inactivated
eonatal calf serum, 0.2% Tween, and 0.04% NaN3. Afterrepeated washing, the membranes were incubated with
the CREB-1 polyclonal antiserum (1:2000; PAN, Germany)for 1.5 h at room temperature, repeatedly washed, and
incubated for 1 h with anti-rabbit antibody Immunopure
R. Donkey (1:2000; Pierce, Rockford, IL), and again
washed. To visualize the protein–antibody complexes the
membrane was treated with the chemiluminiscent sub-
strate “Supersignal Ultra” (Pierce) and exposed with X-
ray film. For loading control a gel was stained with
Coomassie blue.
Quantitation of viral gene expression
Epinephrine-treated and untreated THP-1 cells in-
fected with the HCMV strain RC256 were grown for 72 h,
harvested, and washed three times with PBS. After being
resuspended in 500 ml PM-2 buffer the cells were sub-
jected to five freeze–thaw cycles. After centrifugation to
remove cell debris the protein concentration was mea-
sured using the Bradford reagent kit (Bio-Rad, Germany).
Equal amounts of protein from cell extracts were incu-
bated with ONPG (Sigma, Deisenhofen, Germany). The
b-galactosidase activity was determined as described by
MacGregor et al. (1991).
Statistical analysis
Data are expressed as mean 6 SEM. The Friedman
test and Wilcoxon test for paired samples were used for
comparison of dependent values in follow-up. The Pear-
son coefficient with two-tailed significance levels was
taken for correlation analyses. Differences were consid-
ered significant at P , 0.05.
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